Single-pill telmisartan and amlodipine: A rational combination for the treatment of hypertension

Drugs

Volumn 71, Issue 17, 2011, Pages 2295-2305

  Suárez, Carmen ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

hypertension; Telmisartanamlodipine

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; OBESITY; PERIPHERAL EDEMA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; HYPERTENSION;

EID: 81155123618     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11594510-000000000-00000     Document Type: Review

References (53)

1. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens onmajor cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12): 1410-9 (Pubitemid 40973424)
2. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008 May 17; 336 (7653): 1121-3 (Pubitemid 351731743)
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment ofHigh Blood Pressure: the JNC 7 report. JAMA 2003 May 21; 289 (19): 2560-72 (Pubitemid 37430158)
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25 (6): 1105-87 (Pubitemid 46924065)
5. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004 Jan; 43 (1): 10-7 (Pubitemid 38031904)
6. Banegas JR. Epidemiology of arterial hypertension in Spain: present situation and perspectives [in Spanish]. Hipertensio ́ n 2005; 22 (9): 353-62
7. Coca A. Evolució n del control de la hipertensió n arterial en Españ a: resultados del estudio Controlpres 2001. Hipertensio ́ n 2002; 19 (9): 390-9
8. Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract 2008 May; 62 (5): 781-90 (Pubitemid 351533670)
9. Struijker-Boudier HA, Ambrosioni E, Holzgreve H, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? Int J Clin Pract 2007 Sep; 61 (9): 1592-602 (Pubitemid 47228597)
10. Neutel JM, Saunders E, Bakris GL, et al. The efficacy and safety of low-and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005 Oct; 7 (10): 578-86
11. Neutel JM, Franklin SS, Oparil S, et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006 Dec; 8 (12): 850-7, quiz 8-9
12. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999 Jan 12; 160 (1): 41-6 (Pubitemid 29054225)
13. Burnier M, Hess B, Greminger P, et al. Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.BMC Cardiovasc Disord 2005; 5 (1): 11-13
14. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003 Jun 28; 326 (7404): 1427-31 (Pubitemid 36776153)
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug 4; 353 (5): 487-97 (Pubitemid 41127293)
16. Dezii CM. A retrospective study of persistence with singlepill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000 Sep; 9 (9 Suppl.): 2-6
17. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med 2007 Aug; 120 (8): 713-9 (Pubitemid 47176510)
18. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2006; (4): CD005182
19. Weir MR. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. JHum Hypertens 2007 Oct; 21 (10): 770-9 (Pubitemid 47450002)
20. Egan BM. Combination therapy with an angiotensinconverting enzyme inhibitor and a calcium channel blocker. J Clin Hypertens (Greenwich) 2007 Oct; 9 (10): 783-9
21. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996 Sep 23; 156 (17): 1969-78 (Pubitemid 26318104)
22. Chrysant SG. The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs 2010; 10 (5): 315-20
23. Ahrens K, Bramlage P. Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension. Drugs Today (Barc) 2010 May; 46 (5): 339-50
24. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008; 28 (11): 713-34
25. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in highrisk patients. N Engl J Med 2008 Dec 4; 359 (23): 2417-28
26. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep 10-16; 366 (9489): 895-906 (Pubitemid 41265663)
27. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008 Mar; 10 (3): 185-94
28. Chrysant SG, MelinoM, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COA CH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008 Apr; 30 (4): 587-604 (Pubitemid 351680489)
29. Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000 Aug; 2 (4): 370-7
30. Inoue T, Morooka T, Moroe K, et al. Effect of telmisartan on cholesterol levels in patients with hypertension: Saga Telmisartan Aggressive Research (STAR). Horm Metab Res 2007; 39 (5): 372-6 (Pubitemid 46877854)
31. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.Diabetes Care 2006 Dec; 29 (12): 2592-7 (Pubitemid 44912184)
32. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007 Apr; 29 (4): 563-80 (Pubitemid 47028551)
33. Lacourciere Y. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999 Mar; 53 (2): 99-103 (Pubitemid 29131365)
34. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-59 (Pubitemid 351522739)
35. Littlejohn 3rd TW, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients [published erratum appears in J Clin Hypertens (Greenwich) 2009; 11(8): 458]. J Clin Hypertens (Greenwich) 2009 Apr; 11 (4): 207-13
36. Littlejohn 3rd TW, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 · 4 factorial study. Postgrad Med 2009 Mar; 121 (2): 5-14
37. Neutel J, Mancia G, Black H, et al. Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA Severe HTN Study: Ht.1.04. J Hypertens 2010; 28 e-Suppl. A: e46
38. White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010 Aug; 15 (4): 205-12
39. Littlejohn III T, Ruilope LM, Raskin P, et al. Telmisartan in combination with amlodipine provides a highly effective and well tolerated treatment option for hypertensive patients with diabetes: sub-analysis from a factorial design study [abstract no. P26.313]. Poster presented at the 19th European Meeting on Hypertension; 2009 Jun 12-16; Milan. J Hypertens 2009; 27 Suppl. 3: S275
40. Littlejohn III T, Ruilope LM, Chrysant SG, et al. Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study [abstract no. P26.305]. Poster presented at the 19th European Meeting on Hypertension; 2009 Jun 12-16; Milan. J Hypertens 2009; 27 Suppl. 3: S272
41. Fogari R, Derosa G, Zoppi A, et al. Effect of telmisartanamlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 2007 Apr; 20 (4): 417-22 (Pubitemid 46441757)
42. Neldam S, Lang M, TEAMSTA-5 Study Investigators. Fixeddose combination therapy with telmisartan and amlodipine 5mg in non-responders to amlodipine 5mg provides superior blood pressure reductions to, and is better tolerated than, amlodipine 10mg [abstract no. P26.309]. Poster presented at the 19th EuropeanMeeting on Hypertension; 2009 Jun 12-16; Milan. J Hypertens 2009; 27 Suppl. 3: S273-4
43. Neldam S, Edwards C, TEAMSTA-10 Study Investigators. Switch to a fixed-dose combination therapy with telmisartan and amlodipine provides significant blood pressure reduction and control in patients not adequately controlled with amlodipine 10mg [abstract no. P26.319]. Poster presented at the 19th European Meeting on Hypertension; 2009 Jun 12-16; Milan. J Hypertens 2009; 27 Suppl. 3: S277
44. Neldam S, Edwards C, Jones R. Long-term efficacy and safety profile of single-pill combinations of telmisartan/amlodipine in patients not controlled on amlodipine 10mg: open-label follow-up of TEAMSTA-10 [abstract no. Pp.27.90 plus poster]. 20th European Meeting onHypertension; 2010 Jun 18-21; Oslo. J Hypertens 2010; 28: e474
45. Neldam S, Lang M, Jones R. Long-term efficacy and safety profile of single-pill combinations of telmisartan/amlodipine in patients not controlled on amlodipine 5 mg: open-label followup of TEAMSTA-5 [abstract no. Pp.27.95 plus poster]. 20th European Meeting on Hypertension; 2010 Jun 18-21; Oslo. J Hypertens 2010; 28: e475-6
46. Wang W, Ma L, Zhang Y, et al. The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. J Hum Hypertens 2011; 25: 271-7
47. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000 Sep 26; 102 (13): 1503-10
48. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA2004 Nov 10; 292 (18): 2217-25
49. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 Mar 7; 113 (9): 1213-25
50. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipidlowering treatment to prevent heart attack trial. Hypertension 2006 Sep; 48 (3): 374-84 (Pubitemid 44253729)
51. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19; 363 (9426): 2022-31 (Pubitemid 38781102)
52. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensinreceptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008 Sep 27; 372 (9644): 1174-83
53. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 Sep 18; 359 (12): 1225-37